Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H9T3
UPID:
ELP3_HUMAN
Alternative names:
tRNA uridine(34) acetyltransferase
Alternative UPACC:
Q9H9T3; B4DE19; B4DIG1; E2QRI5; Q53G84; Q6AWB0; Q9BVF7; Q9NVZ1
Background:
Elongator complex protein 3, also known as tRNA uridine(34) acetyltransferase, plays a crucial role in tRNA modifications essential for accurate decoding, protein synthesis, and neurogenesis. It is involved in the acetylation of tRNAs and proteins, influencing neuron migration and cortical development.
Therapeutic significance:
Given its involvement in neurodegenerative disorders like Amyotrophic lateral sclerosis, where it may act as a disease modifier, targeting Elongator complex protein 3 could offer new avenues for therapeutic intervention in such conditions.